The first-in-class oral RIPTAC molecule JNJ-6143 reached a 75% overall response rate and significant declines in PSA in metastatic castration-resistant prostate cancer.
News|Videos|January 4, 2024
Tackling Cancer Care in the Face of Climate Change
Author(s)Leticia Nogueira, PhD, MPH
Leticia Nogueira, PhD, MPH, discusses how healthcare professionals and patients can come together facing the threats of climate change on cancer care.
Advertisement
Climate change presents several hazards to patients with cancer, including disruptions in access to care and higher risk of infection. In an interview with Targeted OncologyTM, Leticia Nogueira, PhD, MPH, scientific director of health services research in the Surveillance & Health Equity Science department at the American Cancer Society, discusses how patients and healthcare providers can manage cancer care in the face of these threats.
Transcription:
Advertisement
Related to this article
Real-world study shows outpatient tarlatamab for relapsed SCLC is feasible, with mostly low-grade CRS, rare ICANS, low ICU use, and similar disease control.
In an interview, David J. Benjamin, MD, explains the findings on gender makeup of NCCN guideline panels he presented at the 2026 ESMO Congress.
Catch up on October 2026 FDA oncology actions: approvals for pirtobrutinib, tucatinib, and dostarlimab, plus BLA and NDA submissions and a new designation.
Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall survival.
The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
Petosemtamab Plus Pembrolizumab Improves OS in PD-L1+ HNSCC
2
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
3
UGN-101 Shows Durable Responses in Urothelial Cancer in 5-Year Follow-Up
4
Late-Breaking Breast Cancer Data at ESMO 2026 Highlight ADCs and Ribociclib
5